Close Menu

NEW YORK (GenomeWeb) – Personal Genome Diagnostics has entered into a strategic collaboration with China's KingMed Diagnostics to use PGDx's Elio tissue complete assay to detect tumor mutational burden and other gene variants.

Separately, PGDx said it has also partnered with Merck as part of a phase II precision oncology study.  

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.